Full Press Release Details
Verify to continue
To continue, please confirm that you're a human (and not a spambot).
Checking if the site connection is secure
vimeo.com needs to review the security of your connection before
proceeding.
KURA Neutral Sentiment
Evaluating ziftomenib in combinations for patients who are newly diagnosed or relapsed/refractory NPM1m or KMT2Ar AML
Key Takeaway: The article discusses the evaluation of ziftomenib in combination therapies for patients with newly diagnosed or relapsed/refractory NPM1m or KMT2Ar AML. However, the content is limited and does not provide detailed insights or findings regarding the study or its implications.
Price reaction · baseline $10.63 (2023-08-23T17:16:00.000Z) · hit during market hours · clean, no other KURA news in the window
day 0 close · peak
-1%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+116%
120-day peak, hindsight
Typical move
5.7%
average across 9 past catalysts
Cash runway
~25 mo
Low dilution risk
Lead asset
Tipifarnib
Phase 2 · Leukemia, Myelomonocytic, Chronic